4/1
12:17 pm
crvs
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Medium
Report
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
4/1
11:15 am
crvs
Rating for CRVS
Medium
Report
Rating for CRVS
3/27
02:11 pm
crvs
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) had its "neutral" rating re-affirmed by analysts at Mizuho. They now have a $3.50 price target on the stock.
Low
Report
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) had its "neutral" rating re-affirmed by analysts at Mizuho. They now have a $3.50 price target on the stock.
3/27
02:11 pm
crvs
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) had its "neutral" rating re-affirmed by analysts at Mizuho. They now have a $3.50 price target on the stock.
Low
Report
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) had its "neutral" rating re-affirmed by analysts at Mizuho. They now have a $3.50 price target on the stock.
3/27
01:20 pm
crvs
Rating for CRVS
Low
Report
Rating for CRVS
3/27
01:20 pm
crvs
Rating for CRVS
Low
Report
Rating for CRVS
3/20
07:13 am
crvs
Rating for CRVS
Medium
Report
Rating for CRVS
3/20
07:13 am
crvs
Rating for CRVS
Medium
Report
Rating for CRVS